Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | TPMT | P51580 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787233 | 1.00 | PKM (0.77) | PKMHTTCA12CA1CA2 | |
| SCHEMBL25139750 | 0.87 | PKM (0.58) | PKMHTTCA12CA1CA2 | |
| SCHEMBL2592861 | 0.87 | PKM (1.00) | PKMHTTCA12CA1CA2 | |
| SCHEMBL2031072 | 0.87 | PKM (0.58) | PKMHTTCA12CA1CA2 | |
| SCHEMBL6559195 | 0.85 | CA12 (0.62) | PKMHTTCA12CA1CA2 | |
| SCHEMBL30708151 | 0.85 | CA12 (0.62) | PKMHTTCA12CA1CA2 | |
| SCHEMBL3714733 | 0.85 | CA12 (0.62) | PKMHTTCA12CA1CA2 | |
| SCHEMBL6559478 | 0.83 | CA12 (0.61) | PKMHTTCA12CA1CA2 | |
| SCHEMBL7356053 | 0.83 | CA12 (0.61) | PKMHTTCA12CA1CA2 | |
| SCHEMBL25139651 | 0.83 | PKM (0.54) | PKMHTTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| EP-4358954-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220283175-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022147334-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| US-9346809-B2 | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors | LEO PHARMA A/S (DK) | 2016-05-24 | — | — | US | disclosed |
| EP-2451813-B1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA AS (DK) | 2014-10-01 | — | — | EP | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | US | disclosed |
| EP-2451813-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | Leo Pharma A/S (DK) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011003418-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178740-A1 | HETEROCYCLIC COMPOUNDS AS JAK RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS | JAK1, JAK2, JAK3 | PKM 1470/4885HTT 1693/4885CA12 3979/4885 |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | PKM 3538/4885HTT 4193/4885CA12 3022/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | PKM 1158/4885HTT 3658/4885CA12 3738/4885 |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | PKM 1158/4885HTT 3658/4885CA12 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.